Estimated annual spending on Lecanemab and its ancillary costs in the Medicare program
A cost analysis suggests Lecanemab, an antidementia medication with modest clinical benefit, could add billions to Medicare spending each year. Beneficiaries without supplemental coverage would face substantial out-of-pocket costs.